Summary
It will be a radically new approach for long-term continuous monitoring of insulin-treated persons with diabetes (ITD) moving from a glucose-only to a multi-metabolite monitoring - glucose, lactate and 3 ß OH-butyrate– paradigm. Multi-metabolite monitoring will also lead to a diabetes therapy breakthrough by algorithmically driving a continuous physiologic insulin delivery by a maintenance-free implanted MEMS pump using the peritoneal route enabling an optimal therapy for subjects with ITD.
Our vision is a fully implantable artificial organ to replace insulin secretion loss by targeting metabolic health instead of mere glucose control and mimicking physiological insulin action. While offering a really burden-free life for insulin-treated children and adults, it is expected to allow a dramatic reduction of metabolic variations, hence a minimization of acute and long-term complications and an abating of the still high mortality of T1D patients.
Unobtrusive living with diabetes will be reached by the calibration-free, implantable, long-term multi-metabolite monitoring solution connected wirelessly to a novel highly miniaturized silicon MEMS micropump, with down to 50 nl stroke volume, able to operate a newly developed U1000 insulin and enabling reservoir refill cycles of 180 days up to 365 days. Both devices hold durable battery operating life of more than 8 years without recharge and are suitable for children. Newly designed control algorithms based upon multiple signal inputs will drive automated insulin delivery without the need of obtrusive meal and physical exercise announcements.
Our vision is a fully implantable artificial organ to replace insulin secretion loss by targeting metabolic health instead of mere glucose control and mimicking physiological insulin action. While offering a really burden-free life for insulin-treated children and adults, it is expected to allow a dramatic reduction of metabolic variations, hence a minimization of acute and long-term complications and an abating of the still high mortality of T1D patients.
Unobtrusive living with diabetes will be reached by the calibration-free, implantable, long-term multi-metabolite monitoring solution connected wirelessly to a novel highly miniaturized silicon MEMS micropump, with down to 50 nl stroke volume, able to operate a newly developed U1000 insulin and enabling reservoir refill cycles of 180 days up to 365 days. Both devices hold durable battery operating life of more than 8 years without recharge and are suitable for children. Newly designed control algorithms based upon multiple signal inputs will drive automated insulin delivery without the need of obtrusive meal and physical exercise announcements.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101115233 |
| Start date: | 01-10-2023 |
| End date: | 30-09-2027 |
| Total budget - Public funding: | 3 885 462,50 Euro - 3 885 462,00 Euro |
Cordis data
Original description
It will be a radically new approach for long-term continuous monitoring of insulin-treated persons with diabetes (ITD) moving from a glucose-only to a multi-metabolite monitoring - glucose, lactate and 3 ß OH-butyrate– paradigm. Multi-metabolite monitoring will also lead to a diabetes therapy breakthrough by algorithmically driving a continuous physiologic insulin delivery by a maintenance-free implanted MEMS pump using the peritoneal route enabling an optimal therapy for subjects with ITD.Our vision is a fully implantable artificial organ to replace insulin secretion loss by targeting metabolic health instead of mere glucose control and mimicking physiological insulin action. While offering a really burden-free life for insulin-treated children and adults, it is expected to allow a dramatic reduction of metabolic variations, hence a minimization of acute and long-term complications and an abating of the still high mortality of T1D patients.
Unobtrusive living with diabetes will be reached by the calibration-free, implantable, long-term multi-metabolite monitoring solution connected wirelessly to a novel highly miniaturized silicon MEMS micropump, with down to 50 nl stroke volume, able to operate a newly developed U1000 insulin and enabling reservoir refill cycles of 180 days up to 365 days. Both devices hold durable battery operating life of more than 8 years without recharge and are suitable for children. Newly designed control algorithms based upon multiple signal inputs will drive automated insulin delivery without the need of obtrusive meal and physical exercise announcements.
Status
SIGNEDCall topic
HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-04Update Date
31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Coördinator)
-
| CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
-
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
-
| FIDAM GMBH
-
| INDIGO DIABETES
-
| UNIVERSITA DEGLI STUDI DI PADOVA - University of Padova
-
| UNIVERSITA DEGLI STUDI DI PAVIA